PubRank

T R Burke

Author PubWeight™ 62.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A 1996 4.11
2 Probes for narcotic receptor mediated phenomena. 9. Synthesis of (+/-)-(3 alpha,6a alpha,11a beta)-1,3,4,5,6,11a-hexahydro-2-methyl-2H-3,6a- methanobenzofuro[2,3-c]azocin-10-ol, an oxide-bridged 5-(m-hydroxyphenyl)morphan. J Med Chem 1986 1.54
3 Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. J Biol Chem 1994 1.43
4 Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc Natl Acad Sci U S A 1998 1.25
5 Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide. Biochemistry 1992 1.18
6 Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol 2000 1.17
7 Coumarin-based inhibitors of HIV integrase. J Med Chem 1997 1.16
8 Protein kinase C-zeta and phosphoinositide-dependent protein kinase-1 are required for insulin-induced activation of ERK in rat adipocytes. J Biol Chem 1999 1.13
9 Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother 2001 1.09
10 Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 2001 1.03
11 Caffeic acid phenethyl ester induces leukocyte apoptosis, modulates nuclear factor-kappa B and suppresses acute inflammation. Neuroimmunomodulation 2000 1.02
12 Purification of the opiate receptor of NG108-15 neuroblastoma-glioma hybrid cells. Proc Natl Acad Sci U S A 1985 1.02
13 Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. J Med Chem 1996 1.00
14 Thermodynamic study of ligand binding to protein-tyrosine phosphatase 1B and its substrate-trapping mutants. J Biol Chem 2000 0.98
15 Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? Biochem Biophys Res Commun 1995 0.97
16 Arylamide inhibitors of HIV-1 integrase. J Med Chem 1997 0.95
17 Chicoric acid analogues as HIV-1 integrase inhibitors. J Med Chem 1999 0.95
18 Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochemistry 1998 0.94
19 Glucose activates mitogen-activated protein kinase (extracellular signal-regulated kinase) through proline-rich tyrosine kinase-2 and the Glut1 glucose transporter. J Biol Chem 2000 0.93
20 F2(Pmp)2-TAM zeta 3, a novel competitive inhibitor of the binding of ZAP-70 to the T cell antigen receptor, blocks early T cell signaling. J Biol Chem 1995 0.92
21 Hydrazide-containing inhibitors of HIV-1 integrase. J Med Chem 1997 0.91
22 Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J Med Chem 1997 0.90
23 Identification of a Mr 58 000 glycoprotein subunit of the opiate receptor. FEBS Lett 1982 0.90
24 Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor. Bioorg Med Chem Lett 2001 0.88
25 Probes for narcotic receptor mediated phenomena 3. Oxide bridged 5-phenylmorphans. NIDA Res Monogr 1984 0.88
26 Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. J Biol Chem 1997 0.88
27 A phosphotyrosyl mimetic peptide reverses impairment of insulin-stimulated translocation of GLUT4 caused by overexpression of PTP1B in rat adipose cells. Biochemistry 1999 0.88
28 QSAR of conformationally flexible molecules: comparative molecular field analysis of protein-tyrosine kinase inhibitors. J Comput Aided Mol Des 1992 0.87
29 Irreversible ligands with high selectivity toward delta and mu opiate receptors. Science 1983 0.87
30 Olefin metathesis in the design and synthesis of a globally constrained Grb2 SH2 domain inhibitor. Org Lett 2001 0.85
31 Morphine tolerance increases mu-noncompetitive delta binding sites. Eur J Pharmacol 1986 0.85
32 Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J Med Chem 1998 0.85
33 Cell protein cross-linking by erbstatin and related compounds. Biochem Pharmacol 1996 0.85
34 Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrob Agents Chemother 1997 0.84
35 Calcium ion dependent covalent modification of calmodulin with norchlorpromazine isothiocyanate. Biochemistry 1983 0.84
36 Radiosynthesis of [18F]3-acetylcyclofoxy: a high affinity opiate antagonist. Int J Appl Radiat Isot 1985 0.84
37 Arylisothiocyanate-containing esters of caffeic acid designed as affinity ligands for HIV-1 integrase. Bioorg Med Chem 2001 0.83
38 Synthesis of 4'- and 5'-hydroxyoxprenolol:pharmacologically active ring-hydroxylated metabolites of oxprenolol. J Med Chem 1979 0.82
39 Probes for narcotic receptor mediated phenomena. 7. Synthesis and pharmacological properties of irreversible ligands specific for mu or delta opiate receptors. J Med Chem 1984 0.82
40 Probes for narcotic receptor mediated phenomena. 12. cis-(+)-3-Methylfentanyl isothiocyanate, a potent site-directed acylating agent for delta opioid receptors. Synthesis, absolute configuration, and receptor enantioselectivity. J Med Chem 1986 0.82
41 Alkyl-substituted gamma-butyrolactones inhibit [35S]TBPS binding to a GABA linked chloride ionophore. Eur J Pharmacol 1984 0.81
42 Cost neutral catastrophic care proposed for Medicare recipients. Rev Fed Am Hosp 1986 0.81
43 Yersinia pestis and approaches to targeting its outer protein H protein-tyrosine phosphatase (YopH). Curr Med Chem 2012 0.80
44 3-[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals. FEBS Lett 1984 0.80
45 Interaction of Alkyl/Arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule. J Pharmacol Exp Ther 1997 0.80
46 Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors. Bioorg Med Chem 1998 0.79
47 Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. J Med Chem 2000 0.79
48 Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, L-O-malonyltyrosine. Biochem Biophys Res Commun 1995 0.79
49 Hydroxylated 2-(5'-salicyl)naphthalenes as protein-tyrosine kinase inhibitors. J Med Chem 1993 0.79
50 The stereoselective disposition of disopyramide in the dog. J Cardiovasc Pharmacol 1981 0.78
51 Pathways of propranolol metabolism. Use of the stable isotope twin-ion GC-MS technique to examine the conversion of propranolol to propranolol-diol by 9000g rat liver supernatant. Res Commun Chem Pathol Pharmacol 1978 0.78
52 Physiological changes which may result from in vivo experimental conditions. Br J Cancer Suppl 1980 0.78
53 Cardiovascular and plasma prolactin responses to stereoisomers of phencyclidine. Pharmacol Biochem Behav 1983 0.78
54 Cellular effects of phosphotyrosine-binding domain inhibitors on insulin receptor signaling and trafficking. Mol Cell Biol 1997 0.78
55 L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides. J Med Chem 1995 0.77
56 HIV-1 integrase and virus and cell DNAs: complex formation and perturbation by inhibitors of integration. Neurochem Res 2009 0.77
57 Procaine isothiocyanate: an irreversible inhibitor of the specific binding of [3H]batrachotoxinin-A benzoate to sodium channels. Neurochem Res 1990 0.77
58 New directions in effective quality of care: patient outcome research. Rev Fed Am Health Syst 1988 0.77
59 Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. J Med Chem 1999 0.77
60 Mechanism of defluorination of enflurane. Identification of an organic metabolite in rat and man. Drug Metab Dispos 1981 0.77
61 Leucine enkephalin noncompetitively inhibits the binding of [3H]naloxone to the opiate mu-recognition site: evidence for delta----mu binding site interactions in vitro. Neuropeptides 1985 0.77
62 Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides. Bioorg Med Chem 1997 0.76
63 Resolution, absolute configuration, and antiarrhythmic properties of the enantiomers of disopyramide, 4-(diisopropylamino)-2-(2-pyridyl)-2-phenylbutyramide. J Med Chem 1980 0.76
64 Implantable oxygen microelectrode suitable for medium-term investigations of post-surgical tissue hypoxia and changes in tumor tissue oxygenation produced by radiotherapy. J Med 1980 0.76
65 The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition. Cancer Res 1995 0.76
66 Phosphonate inhibitors of protein-tyrosine and serine/threonine phosphatases. Biochem J 1995 0.75
67 Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: evidence for a two-site allosteric model. Neuropeptides 1984 0.75
68 Long-term care: the public role and the private initiatives. Health Care Financ Rev 1988 0.75
69 Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo. J Med Chem 1983 0.75
70 Carbon-13 nuclear magnetic resonance studies of spironolactone and several related steroids. Steroids 1980 0.75
71 Utilization of a peptide lead for the discovery of a novel PTP1B-binding motif. J Med Chem 2001 0.75
72 Identification of lymphoid cells in cultured of murine leukocytes and thymus. Cancer Res 1975 0.75
73 Bone marrow toxicity in vitro of chloramphenicol and its metabolites. Toxicol Appl Pharmacol 1982 0.75
74 Reversed-phase preparative chromatography of [D-Ala1]-peptide T amide. J Chromatogr 1988 0.75
75 Reductive dechlorination of chloramphenicol by rat liver microsomes. Drug Metab Dispos 1983 0.75
76 Aromatic hydroxylation of oxprenolol. Quantitation and stereoselectivity in the formation of 4'- and 5-hydroxyoxprenolol in vivo in the rat. Res Commun Chem Pathol Pharmacol 1980 0.75
77 Preparation of rat brain membranes highly enriched with opiate kappa binding sites using site-directed acylating agents: optimization of assay conditions. Neuropeptides 1985 0.75
78 Ionic conditions differentially affect 3H-DADL binding to type-I and type-II opiate delta receptors in vitro. Neuropeptides 1984 0.75
79 Evidence that the delta-selective alkylating agent, fit, alters the mu-noncompetitive opiate delta binding site. Neuropeptides 1985 0.75
80 Synthesis, configuration, and evaluation of two conformationally restrained analogues of phencyclidine. J Med Chem 1988 0.75
81 A survey and critical evaluation of long term care reimbursement policies under Medicaid. J Long Term Care Adm 1975 0.75
82 Phencyclidine-induced catalepsy in pigeons: specificity and stereoselectivity. Eur J Pharmacol 1984 0.75
83 Potent inhibition of protein-tyrosine phosphatase-1B using the phosphotyrosyl mimetic fluoro-O-malonyl tyrosine (FOMT). Bioorg Med Chem Lett 1998 0.75
84 An instrument for measuring directional movement speed under different environmental stimulus conditions. Res Q 1976 0.75
85 Morphine noncompetitively inhibits [3H]leucine enkephalin binding to membranes lacking type-II delta binding sites: evidence for a two-site allosteric model. Neuropeptides 1984 0.75
86 Structural requirements for Tyr in the consensus sequence Y-E-N of a novel nonphosphorylated inhibitor to the Grb2-SH2 domain. Biochem Biophys Res Commun 1999 0.75
87 A new pathway for the oxidative metabolism of chloramphenicol by rat liver microsomes. Drug Metab Dispos 1983 0.75
88 HHS Chief of Staff Burke urges industry to face up to the economic facts of life. Rev Fed Am Health Syst 1988 0.75
89 Medicare cost shifting: you ain't seen nothin' yet. Bus Health 1990 0.75
90 Aromatic hydroxylation of beta-adrenergic antagonists. 4- and 5-hydroxylation of 1-(isopropylamino)-3-[2-(allyloxy)phenoxy]-2-propanol (oxprenolol). J Med Chem 1978 0.75
91 Quality improvement to be key step for Bowen, HHS chief of staff says. Rev Fed Am Health Syst 1986 0.75
92 Aromatic hydroxylation of beta-adrenergic antagonists. Formation of 4'- and 5'-hydroxy-1-(isopropylamino)-3-[2'-allyloxy)phenoxy]-2-propanol from oxprenolol. J Med Chem 1979 0.75
93 Induction of theta-positive murine lymphocytes by a thymic extract. Res Commun Chem Pathol Pharmacol 1976 0.75
94 Synthesis and properties of CAPP1-calmodulin. Methods Enzymol 1987 0.75
95 Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. J Med Chem 1993 0.75
96 Investigation of the mechanism of defluorination of enflurane in rat liver microsomes with specifically deuterated derivatives. Biochem Pharmacol 1980 0.75
97 Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains. Bioorg Med Chem Lett 2000 0.75
98 Preparation of aryl isothiocyanates via protected phenylthiocarbamates and application to the synthesis of caffeic acid (4-isothiocyanato)phenyl ester. J Org Chem 2000 0.75
99 The pattern of [3H]cyclofoxy retention in rat brain after in vivo injection corresponds to the in vitro opiate receptor distribution. Brain Res 1987 0.75
100 Metabolism of beta-adrenergic antagonists. Evidence for an arene oxide-NIH shift pathway in the aromatic hydroxylation of oxprenolol. J Med Chem 1979 0.75
101 Increased affinity of dimeric enkephalins is not dependent on receptor density. Neuropeptides 1985 0.75
102 Effects of phencyclidine on rat prolactin, dopamine receptor and locomotor activity. Life Sci 1983 0.75
103 Tritiated-6-beta-fluoro-6-desoxy-oxymorphone: a highly selective ligand for the opiate mu receptor whose binding is characterized by low nonspecific binding. Neuropeptides 1984 0.75
104 Analysis of styryl-based inhibitors of the lymphocyte tyrosine protein kinase p56lck. Biochem Biophys Res Commun 1991 0.75
105 2,5-Dimethyl-2'-hydroxy-9 alpha- and 9 beta-(3-methylbutyl)-6,7-benzomorphans and N-substituted compounds in the 9 alpha-(3-methylbutyl) series: chemistry, pharmacology, and biochemistry. J Pharm Sci 1987 0.75
106 Oxide-bridged 5-phenylmorphans as probes for narcotic receptor mediated phenomena. NIDA Res Monogr 1990 0.75
107 Conformational analysis of cyclic hexapeptides designed as constrained ligands for the SH2 domain of the p85 subunit of phosphatidylinositol-3-OH kinase. Biopolymers 1996 0.75